Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus

Ida, Satoshi; Kaneko, Ryutaro; Imataka, Kanako; Ôkubo, Kaoru; Shirakura, Yoshitaka; Azuma, Kentaro; Fujiwara, Ryoko; Murata, Kazuya

doi:10.2174/1573399816666200705210006

Cited by 32 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, if sustained, caloric restriction will lead to variable weight loss depending on the partitioning of these calories between lean mass and fat mass. In medical practice, most diets and current pharmacotherapies will lead to some degree of lean mass loss (Figure 2) (6)(7)(8).…”

Section: Role Of Energy E Xpend Iture and Fat Oxidati On In Body Wei ...mentioning

confidence: 99%

“…In large part, the reduction in energy expenditure induced by weight loss is attributable to the decline in lean mass, the metabolically active tissues (26‐28). Even if lifestyle modifications and currently available therapies for weight loss can deliver substantial decreases in fat mass, 15% to 40% of the weight loss represents reductions in lean mass (6‐8) (Figure 2). Resting energy expenditure is reduced by approximately 13 kcal/d for each kilogram of muscle mass lost, in contrast with the much lower 4.5‐kcal/d reduction for each kilogram of fat mass lost (29).…”

Section: Challenges Of Weight Loss and Its Maintenance With Emphasis ...mentioning

confidence: 99%

See 1 more Smart Citation

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

Christoffersen

Sánchez-Delgado

John

et al. 2022

Obesity

View full text Add to dashboard Cite

Lifestyle interventions can reliably produce and sustain only modest (~5%-10%) weight loss (1), necessitating other types of antiobesity interventions, such as pharmacotherapy, to address obesity management. Antiobesity medication development initially relied on observations of weight loss in agents approved for other indications, which resulted in troubled first-generation medications being used for weight management. However, new pharmacological treatments have been emerging based on an understanding of the biology of appetite regulation (2-4). These agents have been developed by taking advantage of their known effects on reducing energy intake and they appear promising in delivering more desirable amounts of weight loss of up to 15% from baseline after 6 to 10 months of treatment (2-4). Apart from weight loss per se, a more specific goal of weight management should be health improvement through a reduction

show abstract

Section: Role Of Energy E Xpend Iture and Fat Oxidati On In Body Wei ...mentioning

confidence: 99%

Section: Challenges Of Weight Loss and Its Maintenance With Emphasis ...mentioning

confidence: 99%

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

Christoffersen

Sánchez-Delgado

John

et al. 2022

Obesity

View full text Add to dashboard Cite

show abstract

“…Guanidine was found to be the active ingredient of French lilac and in the 1950s metformin and phenformin, the two main biguanides, were introduced as a treatment for diabetes. Today metformin is prescribed to almost 120 million people for the treatment of type II diabetes (Ida et al, 2020). Interestingly, retrospective studies have shown that metformin is associated with a decreased cancer risk in diabetic patients (DeCensi et al, 2010).…”

mentioning

confidence: 99%

The common diabetes drug metformin can diminish the action of citral against Rhabdomyosarcoma cells in vitro

Duan

Evison

Taylor

et al. 2020

Phytotherapy Research

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is a rare type of soft tissue sarcoma most commonly found in pediatric patients. Despite progress, new and improved drug regimens are needed to increase survival rates. Citral, a natural product plant oil can induce cell death in cancer cells. Another compound, metformin, isolated originally from French lilac and used by diabetics, has been shown to reduce the incidence of cancer in these patients. Application of citral to RMS cells showed increase in cell death, and RD and RH30 cells showed half maximal inhibitory concentration (IC50) values as low as 36.28 μM and 62.37 μM, respectively. It was also shown that the citral initiated cell apoptosis through an increase in reactive oxygen species (ROS) and free calcium. In comparison, metformin only showed moderate cell death in RMS cell lines at a very high concentration (1,000 μM). Combinatorial experiments, however, indicated that citral and metformin worked antagonistically when used together. In particular, the ability of metformin to quench the ROS induced by citral could lead to the suppression of activity. These results clearly indicate that while clinical use of citral is a promising anti‐tumor therapy, caution should be exercised in patients using metformin for diabetes.

show abstract

“…However, in another study involving 21 T2DM patients undergoing haemodialysis, addition of dulaglutide to insulin therapy significantly decreased FM and SMM, suggesting the sarcopenia risk of this drug 63 . A recent meta‐analysis of randomized controlled trials also indicated that semaglutide was associated with both weight loss and FFM decrease, prompting the need to understand drug‐specific effects on sarcopenic parameters 64 …”

Section: Effects Of Anti‐diabetic Drugs On the Musclementioning

confidence: 99%

“… 63 A recent meta‐analysis of randomized controlled trials also indicated that semaglutide was associated with both weight loss and FFM decrease, prompting the need to understand drug‐specific effects on sarcopenic parameters. 64 …”

Section: Effects Of Anti‐diabetic Drugs On the Musclementioning

confidence: 99%

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Zhang

Zhao

Chen

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Sarcopenia, characterized by loss of skeletal muscle mass, quality, and strength, has become a common hallmark of ageing and many chronic diseases. Diabetes mellitus patients have a higher prevalence of sarcopenia, which greatly aggravates the metabolic disturbance and compromises treatment response. Preclinical and clinical studies have shown differential impacts of anti‐diabetic drugs on skeletal muscle mass, strength, and performance, highlighting the importance of rational therapeutic regimen from the perspective of sarcopenia risk. In this review, we provide an update on the regulation of muscle mass and quality by major anti‐diabetic drugs, focusing primarily on emerging data from clinical studies. We also discuss the underlying mechanisms and clinical implications for optimal selection of anti‐diabetic drugs to reduce the risk of sarcopenia. In view of the lifelong use of anti‐diabetic drugs, we propose that a better understanding of the sarcopenia risk and interventional strategies is worthy of attention in future studies.

show abstract

Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus

Cited by 32 publications

References 48 publications

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss

The common diabetes drug metformin can diminish the action of citral against Rhabdomyosarcoma cells in vitro

Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications

Contact Info

Product

Resources

About